The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Working Group, 2011Gait and Motor Symptoms in Healthy Asymptomatic Relatives of Patients with PD Who Are Carriers of Mutations in the LRRK2 Gene
Objective/Rationale:
Gait disturbances play a major role in the motor manifestation of Parkinson's disease (PD). We aim to explore the possibility that subtle gait alterations are also present in the... -
LRRK2 Challenge, 2011Regulation of LRRK2 Activity by Nitric Oxide-Mediated Protein S-Nitrosylation
Objective/Rationale:
Mutations in the LRRK2 gene are a common cause of familial Parkinson’s disease (PD). Familial mutations can influence the GTPase or kinase activity of LRRK2 which may be... -
MJFF Research Grant, 2011In Vivo Validation of the AAV-alpha-synuclein Vectors Generated by UNC for Distribution to MJFF Supported Research Community
Objective/Rationale:
The Michael J. Fox Foundation would like to generate those tools and reagents that can be of greatest use to PD researchers. Working with Dr. R. Jude Samulski at The University... -
MJFF Research Grant, 2011Nmnat Function in Axonal Neuroprotection
Promising Outcomes of Original Grant:
In the previous application, we tested the hypothesis that gene delivery of NMNAT-1 would protect striatal innervation in 6-OHDA lesioned pre-clinical models and... -
Repositioning Drugs for PD, 2011Droxidopa Treatment for Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Memory, concentration, and other cognitive operations are sometimes impaired in Parkinson's disease (PD), but available treatment options are very limited. This project will test... -
Rapid Response Innovation Awards, 2011Pathogenic Significance of the Hyperpolarization-activated Current (Ih) in the Degeneration of Dopaminergic Neurons
Objective/Rationale:
The neurotoxin MPTP is believed to kill nigral dopaminergic neurons by inhibiting mitochondrial metabolism, thus producing Parkinson’s signs in pre-clinical models. Recent studies...
![Two female doctors talking in the lab.](/sites/default/files/styles/ad_callout_single/public/images/ad/apply-for-grant-404-Large-Image-Callout-A-1.jpg?h=2a1ad497&itok=-_5jZ5iX)
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.